Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder TumorIan M. McElree, Michael A. O’Donnell, Vignesh T. Packiam et al.|Cancers|2024Cited by 7
The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBCIan M. McElree, Vignesh T. Packiam, Ryan L. Steinberg et al.|Bladder Cancer|2025Cited by 5
Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial CarcinomaIan M. McElree, Michael A. O’Donnell, Vignesh T. Packiam et al.|Cancers|2024Cited by 5
Sequential endoluminal gemcitabine and docetaxel vs. Bacillus Calmette–Guérin for the treatment of upper tract carcinoma in situIan M. McElree, Ryan L. Steinberg, Vignesh T. Packiam et al.|Urologic Oncology Seminars and Original Investigations|2024Cited by 3
Assessing the efficacy and safety of sequential intravesical gemcitabine and docetaxel – does time from transurethral resection of bladder tumour to induction matter?Ian M. McElree, Vignesh T. Packiam, Grant Henning et al.|British Journal of Urology|2025Cited by 2